{
    "title": "113_hr5750",
    "content": "The \"Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2014\" allows for the extension of exclusivity periods for drugs approved for new indications for rare diseases or conditions. The Secretary can designate a drug approved for a new indication to prevent, diagnose, or treat a rare disease for extensions under certain conditions. The Secretary can designate a drug for a new indication to prevent, diagnose, or treat a rare disease under specific conditions, and the designation cannot be revoked except in certain circumstances. The Secretary can designate a drug for a new indication for a rare disease, with conditions such as notifying the Secretary of production discontinuance for commercial reasons and making the designation public. The Secretary can designate a drug for a new indication for a rare disease, with conditions such as extending patent periods by 6 months for certain drugs. The drug's patent period may be extended by 6 months after expiration if it is the subject of a listed patent with a certification submitted under specific subsections of section 505. The patent period of a drug can be extended by 6 months after expiration if the patent is found valid and would be infringed in litigation. This extension is in addition to any pediatric or qualified infectious disease product exclusivity periods. The extension of a drug patent can be granted for 6 months after expiration if the patent is valid and would be infringed upon. This extension does not apply if the drug has already received a previous extension. The Secretary must adopt final regulations for this extension within 2 years of enactment, following a specific procedure for rulemaking. The Secretary will issue regulations for drug designation under subsection (a) before promulgating regulations under this section. The term 'rare disease or condition' is defined as in section 526(a)(2). Section 505F of the Federal Food, Drug, and Cosmetic Act applies only to certain circumstances. The Cosmetic Act, as amended, applies to drugs approved under specific sections of the Act. Conforming amendments relate to pediatric exclusivity for drugs approved for new indications for rare diseases or conditions. The Cosmetic Act applies to drugs approved under specific sections, with conforming amendments related to pediatric exclusivity for drugs approved for new indications for rare diseases or conditions. The amendments include extending exclusivity periods and adding 6-month extensions for certain drugs. The Federal Food, Drug, and Cosmetic Act is amended to include extensions of exclusivity periods for drugs approved for new indications for rare diseases or conditions. This also applies to biological products, with added provisions for exclusivity extensions. The Federal Food, Drug, and Cosmetic Act is amended to include extensions of exclusivity periods for drugs approved for new indications for rare diseases or conditions, including biological products. The 6-month extensions described in specific paragraphs are in addition to any extensions under section 505F."
}